Virtual Town Hall: A Discussion with Ultragenyx

Screen Shot 2021-10-30 at 1.09.20 PM

Do you have questions about the recent changes announced by Ultragenyx to their CTD clinical development program? ACD is hosting a virtual town hall event on December 17th from 2-3 pm PT with Ultragenyx representatives to answer your questions. We will hear from the following Ultragenyx team members:

  • Marcus Andrews, PhD, Senior Director, Non-Clinical Sciences, Pharmacology/Toxicology
    Marcus Andrews, PhD, Senior Director, Non-Clinical Sciences, Pharmacology/Toxicology, has been at Ultragenyx for almost 5 years, having built his experience supporting the non-clinical development of human pharmaceuticals and therapeutics at Pfizer and Eli Lilly for over a decade. Growing from academic roots at the lab bench between Canada and the UK, researching mechanisms of neuroendocrine development and hormone feedback, he has enjoyed the challenge of applying his scientific experiences to navigating the drug development and regulatory landscape with a number of pharmaceutical modalities, including small molecules, peptides/biologics and nucleic acids, in support of a range of clinical indications from COPD, diabetes and rare diseases such as CTD. At Ultragenyx, Marcus works in the Non-Clinical Sciences group, which is part of the Pharmacology/Toxicology division of Ultragenyx’s larger Translational Sciences organization, and has been involved in the non-clinical development of the CTD program for a number of years.
  • Hilary Beggs, PhD, Executive Director, Program Team Leader
    Hilary recently joined Ultragenyx in August 2021 from Calico, an Alphabet/Google company. At Calico, Hilary was a Program Team Leader accountable for the strategic, scientific and operational leadership of therapeutic programs in partnership with AbbVie that focused on age-related disease. Prior to that she was a Director at Pfizer/Rinat with experience advancing programs from discovery research through Phase 2 in oncology and non-oncology indications across multiple modalities (antibody, bispecific, ADC, small molecule). Hilary earned her PhD in Neuroscience from UNC-Chapel Hill and was a postdoctoral fellow and faculty member at the University of California, San Francisco (UCSF). At Ultragenyx, Hilary is currently an Executive Director, Program Team Leader working on programs including UX068 for CTD.
  • Melanie Brandabur, MD, Senior Medical Director, Global Clinical Development
    Melanie Brandabur, MD joined Ultragenyx in 2014. She received her BA degree from the University of Illinois in Urbana and her MD degree from Rush Medical College in Chicago. She completed her neurology residency and Movement Disorders and Neuropharmacology fellowship at Rush-Presbyterian-St. Luke’s Medical Center in Chicago. This was followed by a post-doctoral basic sciences fellowship in Neurodegenerative Diseases. During her clinical career as a specialist in Parkinson’s disease and Movement Disorders, Dr. Brandabur served as the Medical Director for three National Parkinson Foundation Centers of Excellence: at the University of Illinois, at Alexian Neurosciences Institute and at the Parkinson’s Institute in Sunnyvale, California. Dr. Brandabur is currently a Senior Medical Director in Global Clinical Development at Ultragenyx Pharmaceutical, where she works on the development of therapeutic agents for neurodevelopmental rare diseases, including CTD.

Register and submit your questions below.

Not ready to submit questions yet? Send them by November 17th to